Literature DB >> 9018118

Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas.

S G Diez de Medina1, D Chopin, A El Marjou, A Delouvée, W J LaRochelle, A Hoznek, C Abbou, S A Aaronson, J P Thiery, F Radvanyi.   

Abstract

Growth factors and growth factor receptors are involved in tumor progression. The fibroblast growth factor receptor 2 gene encodes distinct isoforms. The isoforms which bind KGF (keratinocyte growth factor or FGF-7) are called KGF-R or FGFR2b. KGF-R is expressed in different epithelia and is involved in the control of epithelial-mesenchymal interactions. Expression of KGF-R mRNA was examined in normal human bladder and transitional cell carcinoma of the bladder (TCC) by semi-quantitative RT-PCR using TFIID and GAPDH as internal standards. In normal bladder, the KGF-R mRNA was detected in the urothelium but not in the underlying stroma. In TCCs, the level of KGF-R mRNA was generally either normal or low. Eighteen out of 54 TCCs had a KGF-R mRNA level below 30% of that found in normal urothelium. This decrease in KGF-R mRNA was not accompanied by an increase in BEK (FGFR2c) mRNA, the other major splice variant of the fibroblast growth factor receptor 2 gene. Expression of the KGF-R was also monitored by immunohistochemistry using a functional KGF-immunoglobulin chimera. The receptor was uniformly expressed throughout the normal urothelium except for the umbrella cells. Immunoreactivity for KGF-R was found to be negative in tumors with low levels of KGF-R mRNA, while the peritumoral normal urothelium was positive. Among patients with muscle invasive tumors, those exhibiting a low level of KGF-R mRNA had a significantly higher proportion of cancer deaths. Our results suggest that decreased expression of KGF-R can be considered as a marker of tumor progression in muscle invasive TCCs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9018118     DOI: 10.1038/sj.onc.1200830

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

Review 1.  Sleeping beauty: awakening urothelium from its slumber.

Authors:  Zarine R Balsara; Xue Li
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-25

2.  Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.

Authors:  H Fujisawa; M Kurrer; R M Reis; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis.

Authors:  Y Zhang; H Wang; S Toratani; J D Sato; M Kan; W L McKeehan; T Okamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

4.  The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.

Authors:  Richard Grose; Vera Fantl; Sabine Werner; Athina-Myrto Chioni; Monika Jarosz; Robert Rudling; Barbara Cross; Ian R Hart; Clive Dickson
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

5.  Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.

Authors:  Christine Spiegelberg; Johannes Giedl; Nadine T Gaisa; Anja Rogler; Marc-Oliver Riener; Thomas Filbeck; Maximilian Burger; Petra Ruemmele; Arndt Hartmann; Robert Stoehr
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

6.  Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Authors:  Michael G Gartside; Huaibin Chen; Omar A Ibrahimi; Sara A Byron; Amy V Curtis; Candice L Wellens; Ana Bengston; Laura M Yudt; Anna V Eliseenkova; Jinghong Ma; John A Curtin; Pilar Hyder; Ursula L Harper; Erica Riedesel; Graham J Mann; Jeffrey M Trent; Boris C Bastian; Paul S Meltzer; Moosa Mohammadi; Pamela M Pollock
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.

Authors:  Qi Zhao; Otavia L Caballero; Ian D Davis; Eric Jonasch; Pheroze Tamboli; W K Alfred Yung; John N Weinstein; Robert L Strausberg; Jun Yao
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

8.  Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer.

Authors:  Darren C Tomlinson; Fiona R Lamont; Steve D Shnyder; Margaret A Knowles
Journal:  Cancer Res       Date:  2009-05-19       Impact factor: 12.701

Review 9.  The role of fibroblast growth factors in tumor growth.

Authors:  M Korc; R E Friesel
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

Review 10.  A place for precision medicine in bladder cancer: targeting the FGFRs.

Authors:  Erica di Martino; Darren C Tomlinson; Sarah V Williams; Margaret A Knowles
Journal:  Future Oncol       Date:  2016-07-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.